Tessera Defense & Homeland Security Inc. (HLSQ)
Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.
Sector: Services-Prepackaged Software
Industry: Biotechnology
Tessera Defense and Homeland Security Inc
OTC:HLSQHealthcare · Biotechnology
AHAfter hours+0.00%$0.0244
Prev close$0.0224+8.93%Close$0.02440.00%Now$0.0244
Close$0.0244+8.93%
Mkt Cap$634K
EV-
Float10.01M
O/S26M
VOL297K sh
$ Vol$7K
RVOL0.22×
Inst Own0.6%
SI0.9%
Net Cash/Sh-
Dilution
MCap$634KFloat10.01MO/S26M
Dilution